8 June 2023

Manus Neurodynamica raises £2.6m to commercialise its NeuroMotor Pen device.

Northstar Ventures and Par Equity co-led the investment round to support international expansion and US regulatory clearance.

£2.6M

Share allotment filed at Companies House

Manus Neurodynamica develops medical devices designed to aid in the diagnosis and monitoring of neuromotor disorders such as Parkinson disease.

Manus Neurodynamica has secured £2.6m in funding to drive the commercialisation of its NeuroMotor Pen. The investment round was co-led by Northstar Ventures and Par Equity, with additional participation from SIS Ventures, Scottish Enterprise, and Old College Capital.

The capital will support the company expansion into European pharmacy retail and global clinical markets, as well as preparations for US regulatory clearance and trials. Additional funds will be directed towards adapting the technology for immunotherapy applications and other neurological conditions such as Alzheimer disease.

From the founder

"I’d like to thank Manus’ existing investors for supporting the Company’s commercialisation programme of our unique NeuroMotor PenTM , building on previous support we received in 2021. This year is set to be an exciting one, with partnerships already secured, and we truly believe our non-invasive and CE-marked product can have a huge impact on patients and tackle the unmet need for a quick, inexpensive device that can detect neurological conditions, particularly given the ageing global population."

Rutger Zietsma

CEO at Manus Neurodynamica

Investor perspective

"At Northstar Ventures we back businesses that are reimagining the future of healthcare, with a particular focus on healthy ageing. Having relocated its North East office from Durham to Gosforth in Newcastle to accommodate a growing team, we are excited by the potential impact Manus can have on those with neurological conditions and we were delighted to further support its mission."

Richard Charnley

Investment Director, Northstar